Literature DB >> 11480882

Definitions of antidepressant treatment response, remission, nonresponse, partial response, and other relevant outcomes: a focus on treatment-resistant depression.

A A Nierenberg1, L M DeCecco.   

Abstract

Multiple definitions have been used to characterize the outcome of treatments for depression. Beyond the simple criterion of a statistically significant improvement in depression rating scale scores, researchers have had to use more clinically relevant categorical outcomes: response (without remission), remission, nonresponse, partial response, relapse, recurrence, recovery, and, more recently, depressive breakthrough. This article reviews the definitions of these terms and their relevance for the study of treatment-resistant depression.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11480882

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  83 in total

Review 1.  Methodological challenges in studying recurrence of low back pain.

Authors:  Radoslaw Wasiak; Glenn S Pransky; Barbara S Webster
Journal:  J Occup Rehabil       Date:  2003-03

Review 2.  Role of pharmacogenomics in individualising treatment with SSRIs.

Authors:  Dalu Mancama; Robert W Kerwin
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

3.  A proposed model for economic evaluations of major depressive disorder.

Authors:  Hossein Haji Ali Afzali; Jonathan Karnon; Jodi Gray
Journal:  Eur J Health Econ       Date:  2011-06-02

4.  The need to develop more sensitive tools to accurately detect clinical response to treatment in ADHD.

Authors:  Rongwang Yang; Shujiong Mao; Rong Li; Zhengyan Zhao
Journal:  CNS Drugs       Date:  2012-02-01       Impact factor: 5.749

5.  Prevalence of obstructive sleep apnea in suicidal patients with major depressive disorder.

Authors:  William V McCall; Ruth M Benca; Meredith E Rumble; Doug Case; Peter B Rosenquist; Andrew D Krystal
Journal:  J Psychiatr Res       Date:  2019-06-19       Impact factor: 4.791

6.  Translating evidence on depression and physical symptoms into effective clinical practice.

Authors: 
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2007

7.  A placebo-controlled crossover study of iloperidone augmentation for residual anger and irritability in major depressive disorder.

Authors:  Dawn F Ionescu; Maurizio Fava; Daniel Ju Hyung Kim; Lee Baer; Richard C Shelton; Cristina Cusin
Journal:  Ther Adv Psychopharmacol       Date:  2016-02

8.  Relationship between amygdala responses to masked faces and mood state and treatment in major depressive disorder.

Authors:  Teresa A Victor; Maura L Furey; Stephen J Fromm; Arne Ohman; Wayne C Drevets
Journal:  Arch Gen Psychiatry       Date:  2010-11

9.  Long-term course and outcome of obsessive-compulsive patients after cognitive-behavioral therapy in combination with either fluvoxamine or placebo: a 7-year follow-up of a randomized double-blind trial.

Authors:  Michael Rufer; Iver Hand; Heike Alsleben; Anne Braatz; Jürgen Ortmann; Birgit Katenkamp; Susanne Fricke; Helmut Peter
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2004-11-12       Impact factor: 5.270

10.  Continuation and long-term maintenance treatment with Hypericum extract WS 5570 after successful acute treatment of mild to moderate depression--rationale and study design.

Authors:  S Kasper; A Dienel; M Kieser
Journal:  Int J Methods Psychiatr Res       Date:  2004       Impact factor: 4.035

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.